Order #921044

docx

School

Moi University *

*We aren’t endorsed by this school

Course

MISC

Subject

Biology

Date

Nov 24, 2024

Type

docx

Pages

Uploaded by ProfessorChinchillaPerson802

Genomics Guided Treatment (MEDI6234) 1 Genomics Guided Treatment (MEDI6234) By [Name] Course Professor’s Name Institutional Location of Institution Date

Genomics Guided Treatment (MEDI6234) 2 Genomics Guided Treatment (MEDI6234) Genomic medicine is a relatively new medical subspecialty that bases disease treatment decisions on analysis of genomic data. Patient stratification is accomplished through the integration of genetic, clinical, and molecular data, which subsequently enables the development of tailored treatment strategies based on an individual's genomic profile. In addition, sequencing the genome can be used to evaluate pathogenicity, which involves locating the genetic mutations that are accountable for the development of diseases. In impersonalized medicine, many sorts of biomarkers are employed to assist in disease diagnosis, prognosis, and the choice of treatment. Genomic information paves the way for the selection of medications tailored for particular genotypes, which ultimately results in increased therapeutic efficacy and a better understanding of the development of drug resistance. Finally, an evaluation of analytical approaches and strategies for patient stratification is presented, which makes it possible to achieve the best possible drug response while also reducing the risk of adverse drug reactions. While addressing each of these five learning outcomes, the purpose of this study is to compare and contrast the application of genomics in the treatment of cancer and non-cancer disorders. Integrating genetic, clinical, and molecular data for patient classification is a potent tool for illness analysis and management. The clinical picture of a patient can be better comprehended by merging these data sets (1). In order to better understand a patient's health and how it may respond to therapies, it is helpful to combine genomic data from their DNA with their clinical diagnosis and medical history. Besides, illness subtypes and patient stratification based on genetics can be discovered through the integration of genomic, clinical, and molecular data. For instance, molecular data from a tumor and genetic data from a patient's blood can be used together to determine which

Genomics Guided Treatment (MEDI6234) 3 subtypes of cancer are more likely to be responsive to a given treatment (1). The optimum course of treatment for each individual patient can be determined with the use of this classification. Biomarkers and prognosis of patient outcomes can be found through the combination of genetic, clinical, and molecular data. Genomic data from a patient's DNA can be combined with other information about the patient, such as their medical history and imaging results, to help doctors anticipate how well a patient will respond to a treatment or whether they will develop a disease (2). Better treatment decisions and hence better patient outcomes are facilitated by this. Furthermore, pharmacological targets for the development of new therapeutics can be identified by integrating genetic, clinical, and molecular data. Genomic data from a patient's DNA, in conjunction with the patient's medical history and imaging data, can help pinpoint causal genes (1). This can be utilized to create novel medications that specifically target these genes, with the hope of bettering patient outcomes. Personalized treatment can now be enhanced by the combination of genetic, clinical, and molecular data. Genetic indicators for disease can be found by merging a patient's genomic data with their medical history and imaging data (3). Based on this information, we can create individualized therapies that are safe and effective for every patient. Genome sequencing is a powerful method for determining a microbe's potential to cause disease. Researchers and geneticists can determine the genetic factors responsible for a microbe's pathogenicity by sequencing its genome (2). The effects of a microbe on humans and other species can be better predicted if one has a firm grasp on the genetic factors responsible for the pathogenicity of the microorganism.

Your preview ends here

Eager to read complete document? Join bartleby learn and gain access to the full version

Access to all documents
Unlimited textbook solutions
24/7 expert homework help

Genomics Guided Treatment (MEDI6234) 4 Genome sequencing can also shed light on the evolutionary links between different harmful bacteria. Geneticists and researchers can tell the degree of similarity between microorganisms by comparing the sequencing of their genomes (3). This is significant because it may shed light on the potential interactions between different types of bacteria or between microorganisms and other creatures in the environment. In addition, the virulence of microbes can be better understood by genome sequencing. Geneticists and researchers can tell how dangerous a bacterium is by comparing its genome sequence to that of other, more dangerous strains . This is significant because it can shed light on the possible harm that the bacterium may cause to people and other organisms. Antibiotic resistance is another crucial topic that can be uncovered by genome sequencing. Researchers and geneticists can tell how resistant a microbe is to antibiotics by comparing its genome sequence to that of strains already known to be resistant. This is significant because it may shed light on the microbe's propensity to develop resistance to particular drugs. Furthermore, genomic sequencing can shed light on whether or not a certain microbe is a potential pathogen. Geneticists and researchers can tell how dangerous a microbe is by comparing its genome sequence to that of known pathogenic strains (4). Since this may shed light on the microbe's capacity to infect humans and other animals, it is of great importance. The ability of microbes to evolve and adapt to new environments can be revealed by sequencing their genomes. Researchers and geneticists can tell how adaptable a microbe is by comparing its genome sequence to that of other strains known to be flexible (4). This is significant because it can shed light on whether or not the bacterium has the potential to develop resistance to specific antibiotics or to become more harmful in specific conditions.

Genomics Guided Treatment (MEDI6234) 5 The ability of bacteria to infect and disseminate to new hosts can also be learned through sequencing the genome. Geneticists and researchers can tell how contagious a microbe is by comparing its genome sequence to that of other strains of the same type that are known to be contagious (5). Since this may shed light on the microbe's potential for transmission from host to host, it is of great significance. Furthermore, genomic sequencing can shed light on a microbe's adaptability to a variety of environments. Geneticists and researchers can tell how resistant a microbe is to its environment by comparing the genome sequence to that of other strains known to be resistant (5). This is significant since it can shed light on the microbe's capacity for survival under various settings. Finally, knowledge of a microbe's capacity for acquiring additional genetic information can be gleaned from its genome sequence. Geneticists and researchers can tell how susceptible an organism is to mutation by comparing its genome sequence to that of other known changeable strains (6). This is significant because it may shed light on the likelihood of the microbe acquiring new genetic information and so increasing its pathogenicity. Biomarkers are biological substances used in the diagnosis and treatment of a wide variety of medical disorders by measuring physiological processes. Personalized medicine is a method of medical care that tailors treatments and therapies to each patient based on factors such as their genetic composition and way of life (7). Using biomarkers to diagnose a patient quickly and treat them specifically are two of the many benefits of customized medicine. Genetic markers, which are differences in an individual's genetic code that can be used to predict their likelihood of getting particular diseases, are the most widely utilized biomarkers. Informed by genetic markers, doctors can better assess a patient's prognosis and

Genomics Guided Treatment (MEDI6234) 6 select the most appropriate therapy options for them (7). The use of genetic markers to predict an individual's susceptibility to a disease and guide treatment planning has the potential to completely transform the field of personalized medicine. Imaging biomarkers are another form of diagnostic tool in personalized medicine. Biomarkers found using imaging techniques are important for diagnosing and tracking the course of a patient's disease. Cancer diagnosis and monitoring are only two of the many areas where imaging biomarkers come in handy, as they can reveal important details regarding the size and location of tumors or other abnormalities (8). Alterations in organs or tissues over time can be detected using imaging biomarkers, which can shed light on the development of a disease. A patient's response to treatment can also be monitored with the help of biomarkers. Biomarkers of response let doctors gauge how well a treatment is working and whether or not a patient is benefiting from it (7). The effectiveness of a patient's treatment can be assessed by monitoring response biomarkers, which are routinely evaluated at regular intervals. Biomarkers of response can be helpful in deciding whether a treatment should be continued as-is or modified. Metabolomics as a biomarker is a novel and developing field of personalized medicine. Metabolites are tiny chemicals that are created as a byproduct of metabolic activity in cells, and their study is referred to as metabolomics. To get insight into the metabolic processes taking place in the body, metabolomics can be utilized to quantify the amounts of metabolites in a patient's blood or other physiological fluids (8). Beneficial information about a patient's health can be gleaned via metabolomics, which can be used to detect changes in metabolic activity that may be related with particular disorders or diseases.

Your preview ends here

Eager to read complete document? Join bartleby learn and gain access to the full version

Access to all documents
Unlimited textbook solutions
24/7 expert homework help

Genomics Guided Treatment (MEDI6234) 7 Last but not least, proteomics represents a new field of biomarker research for use in customized treatment. Proteins are macromolecules used by cells to perform a wide range of functions, and their study is known as proteomics. Measuring the concentration of proteins in a patient's blood or other bodily fluids using proteomics can reveal important information about the physiological processes taking place in that patient's body (9). Proteomics is a powerful tool for diagnosing illnesses and other medical issues because it can detect subtle but meaningful changes in protein levels. With the help of genomic data, doctors can choose medications that are specifically designed to treat patients with a given genotype. The term "genomics" refers to research into the structure and function of an organism's complete genome (9). A person's genome can be sequenced to help doctors discover the underlying causes of sickness and predict how their bodies will react to various therapies. With this information, doctors may prescribe the most effective medication to each individual patient. Pharmacogenomics refers to the practice of using genetic data in drug prescription (10). This emerging area of medicine has the potential to dramatically alter the therapeutic process. Taking into account an individual's genetic composition allows doctors to determine the best appropriate medicine, dosage, and administration method. This can be useful in lowering the potential for adverse effects brought on by drug-gene interactions. Evidence from the genome can also shed light on the development of resistance to treatment. When bacteria, viruses, or other organisms develop the ability to live and reproduce in the presence of a medicine that would ordinarily kill them, this phenomenon is known as drug resistance (10). The development of drug resistance as a result of this is a serious issue in the fight against infectious diseases. Genome sequencing of drug-resistant

Genomics Guided Treatment (MEDI6234) 8 organisms has allowed researchers to pinpoint the specific mutations that confer resistance and inform the design of new antimicrobial drugs. There are still certain obstacles to be overcome, but there is no denying the promise of genetic information in guiding the selection of medications for specific genotypes and explaining the development of drug resistance. The high price and high level of complexity of genomic sequencing is one of the biggest obstacles (11). Because of its high cost and lengthy processing time, genomic sequencing is not always feasible for use in selecting medications for individual patients. In addition, it is not easy to forecast how an individual would react to a medication due to a lack of information on the interactions between various genes and pharmaceuticals (10). It is crucial in drug development to stratify patients for optimal therapeutic response or adverse drug responses. Knowing what elements affect a drug's reaction and then devising plans to maximize that drug's efficacy in the target population is what this procedure is all about. Adverse drug reaction risk assessment and patient stratification can be performed using a variety of analytical methods. Patient stratification can be improved with the help of pharmacogenetics, the study of how individual differences in physiology and heredity influence drug response. The process involves the examination of a patient's DNA in order to predict whether or not they will have a positive response to a medicine, or whether they will be more susceptible to negative effects (12). An individual's susceptibility to a drug-induced adverse event, for instance, could be predicted by a genetic marker. Find out which patients need closer monitoring or a different medication by using this method. Patient factors including age, gender, weight, ethnicity, and medical history can also be used to stratify individuals for optimal drug response. For instance, if a medicine is found to be more successful in younger patients, then it would be prudent to pay special attention to

Genomics Guided Treatment (MEDI6234) 9 their progress. Some ethnic groups may respond better to a medicine than others, so it's important to keep a careful eye on such people as well. Furthermore, demographic characteristics can be employed in population-based pharmacokinetic studies to evaluate the variability in drug exposure. To learn about drug absorption, distribution, metabolism, and elimination, researchers measure drug concentrations in the blood of study participants (13). By using this data, the drug's dosage and administration schedule can be fine-tuned for maximum efficacy. Finally, pharmacovigilance studies can determine whether or not a medicine is safe for its target population. To conduct these analyses, researchers track and record information about drug reactions in the general population over time (14). This information can be used to assess the drug's safety profile and make necessary adjustments to the dosage and administration schedule. One crucial part of creating a new treatment is figuring out how to divide up patients into groups based on their likelihood of experiencing positive or negative side effects from taking the medicine. Risk of adverse medication reactions can be evaluated using several methods of analysis, such as pharmacogenetics, patient characteristics, population-based pharmacokinetic studies, predictive analytics, and pharmacovigilance research (15). These methods can improve confidence that the medicine will be well tolerated and productive in the target group. These initiatives can only be successful if based on up-to-date and complete information about the population as a whole. This contains information about the medicine itself, as well as details about the patient and their medical history (16). It is also crucial to have access to appropriate technology and methods for analyzing this data and drawing reasonable conclusions.

Your preview ends here

Eager to read complete document? Join bartleby learn and gain access to the full version

Access to all documents
Unlimited textbook solutions
24/7 expert homework help

Genomics Guided Treatment (MEDI6234) 10 Although difficult, patient stratification for optimal medication response or adverse drug reactions is essential for a drug's success and safety. Adverse drug reaction risk assessment and patient stratification can be performed using a variety of analytical methods (17). To ensure that the pharmaceuticals they create are safe and effective for their target demographic, pharmaceutical companies need to employ these methods and have access to the appropriate data and tools. Conclusively, patient stratification and customized treatment can both benefit from the integration of genetic, clinical, and molecular data. To better understand a patient's state and find disease subgroups that may respond better to various treatments, it is necessary to combine these data sets. The sequencing of a microorganism's genome is a crucial method for determining its virulence. Geneticists and researchers can learn a lot about the relationships between different microbes, as well as their virulence, antibiotic resistance, pathogenicity, adaptability, transmissibility, environmental resistance, and mutability, simply by comparing the sequences of their genomes. To diagnose, track, and even foretell the onset of a wide variety of diseases and health problems, biomarkers are an indispensable tool in personalized medicine. Genetic markers, imaging biomarkers, response biomarkers, metabolomics, and proteomics are only few of the many types of biomarkers currently available and under development for use in personalized medicine. Genomic data can be used to determine which treatments will work best against a given genotype, and it can also shed light on how resistance to drugs develops. This may result in novel approaches to combating drug-resistant infections and more efficient and tailored treatments for individual patients. An essential part of developing a new treatment is identifying how to divide up patients into groups based on their potential for a positive or negative response to the medication. Risk of adverse medication reactions can be evaluated using several methods of analysis, such as

Genomics Guided Treatment (MEDI6234) 11 pharmacogenetics, patient characteristics, population-based pharmacokinetic studies, predictive analytics, and pharmacovigilance research.

Genomics Guided Treatment (MEDI6234) 12 References 1. Stark, Z., Dolman, L., Manolio, T.A., Ozenberger, B., Hill, S.L. et al. 2019. Integrating Genomics into Healthcare: A Global Responsibility, AJHG.104(1), pp.13 - 20. https://doi.org/10.1016/j.ajhg.2018.11.014 2. The African Academy of Sciences. 2021. A framework for the implementation of genomic medicine for public health in Africa, ASP Policy Paper 1, 2020. [Online]Available at: https://www.aasciences.africa/sites/default/files/Publications/A%20Framework%20for %20the%20Implementation%20of%20Genomic%20Medicine%20for%20Public%20Health %20in%20Africa.pdf 3. Noviani, M., Chellamuthu, V.R., Albani, S. and Low, A.H.L. 2022. Toward Molecular Stratification and Precision Medicine in Systemic Sclerosis. Front. Med.,9:911977. 4. Alfano, C., Farina, L. and Petti, M. 2023. Networks as Biomarkers: Uses and Purposes.Genes14(429), pp.1 - 11. https://doi.org/10.3390/genes14020429 5. Ferdinand, A.S., Kelaher, M., Lane, C.R., de Silva, A.G., Sherry, N.L. et al. 2021. An implementation science approach to evaluating pathogen whole genome sequencing in public health. Genome Med.,13(121), pp.1 - 11. https://doi.org/10.1186/s13073-021-00934-7 6. Nwadiugwu, M.C. and Monteiro, N. 2022. Applied genomics for identification ofvirulent biothreats and for disease outbreak surveillance. Postgrad Med J.,0, pp.1 -7. https://doi:10.1136/postgradmedj-2021-139916 7. Yadav, S., Raazi, Z., Shivaraj, S.M., Somani, D., Prashant, R., Kulkarni, A., Kumar, R., Biradar, S., Desai, S. and Kadoo, N. 2023. Whole Genome Sequencing and Comparative Genomics of Indian Isolates of Wheat Spot Blotch Pathogen Bipolaris sorokiniana Reveals

Your preview ends here

Eager to read complete document? Join bartleby learn and gain access to the full version

Access to all documents
Unlimited textbook solutions
24/7 expert homework help

Genomics Guided Treatment (MEDI6234) 13 Expansion of Pathogenicity Gene Clusters. Pathogens,12(1), pp.1 - 20. https://doi.org/10.3390/pathogens12010001 8. Koulis, C., Yap, R., Engel, R., Jardé, T., Wilkins, S., Solon, G., Shapiro, J.D., Abud, H. and McMurrick, P. 2020. Personalized Medicine—Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer. Cancers,12(4), 812. https://doi.org/10.3390/cancers12040812 9. Bodaghi, A., Fattahi, G. and Ramazani, A. 2023. Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases. Heliyon,9(2), pp.1 - 18. https://doi.org/10.1016/j.heliyon.2023.e13323 10. Laigle, L., Chadli, L. and Moingeon, P. 2023. Biomarker-driven development of new therapies for autoimmune diseases: current status and future promises, Expert Rev. Clin.Immunol.,19(3), pp.305 - 314, https://doi.org/10.1080/1744666X.2023.2172404 11. Berger, M.F. and Mardis, E.R. 2018. The emerging clinical relevance of genomics in cancer medicine. Nature reviews. Clin. Oncol.,15(6), pp.353-365. https://doi.org/10.1038/s41571-018-0002-6 12. Hendriksen, R.S., Bortolaia, V., Tate, H., Tyson, G.H., Aarestrup, F.M. and McDermott,P.F. 2019. Using Genomics to Track Global Antimicrobial Resistance. Front. Public Health ,7(242), pp.1 - 17. https://doi.org/10.3389/fpubh.2019.00242 13. Ko, Y.K. and Gim, J.-A. 2022. New Drug Development and Clinical Trial Design by Applying Genomic Information Management. Pharmaceutics,14(1539), pp.1 - 20. https://doi.org/10.3390/pharmaceutics14081539

Genomics Guided Treatment (MEDI6234) 14 14. Waddington, C., Carey, M.E., Boinett, C.J., Higginson, E., Veeraraghavan, B. and Baker,S. 2022. Exploiting genomics to mitigate the public health impact of antimicrobial resistance. Genome Med.,14(15), pp.1 - 14. https://doi.org/10.1186/s13073-022-01020-2 15. Osanlou, R., Walker, L., Hughes, D.A., Burside, G. and Pirmohamed, M. 2022. Adversedrug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions BMJ Open,12, pp.1 - 7. 16. Valeanu, A., Damian, C., Marineci, C.D. and Negres, S. 2020. The development of a scoring and ranking strategy for a patient-tailored adverse drug reaction prediction in polypharmacy. Sci Rep.,10(9552), pp.1-11. https://doi.org/10.1038/s41598-020-66611-8 17. Kim, H.R, Sung, M., Park, J., Jeong, K., Kim, H.H., Lee, S. and Park, Y.R. 2022.Analyzing adverse drug reaction using statistical and machine learning methods: A systematic review. Medicine,101(25), pp.1 - 14.

Order #921044

Related Documents